LAUSANNE, Switzerland, September 11, 2014 /PRNewswire/ --
Sophia Genetics, the European leader in Data Driven Medicine, has significantly expanded its European customer base through its first deal with the NHS in the United Kingdom and an agreement with a leading Turkish laboratory. This follows a surge in demand for the company's Clinical Genomics offerings among laboratories and hospitals in Germany, France and Italy, with additional customer relationships in these countries established in August.
These customers now gain access to Sophia Genetics' innovative Data Driven Medicine platform, which offers securely-hosted Software as a Service module covering the bioinformatics analysis protocol, the validation and quality control process, the presentation of results of genetic tests to clinicians and the protection of patient DNA sequence data through safe storage and sharing.
Jurgi Camblong, CEO of Sophia Genetics said, "As Next Generation Sequencing becomes more common, we are seeing more oncologists and clinicians demand the degree of accuracy and readability that Sophia Genetics offers, and we take pride in the fact that we provide them with unique reports they can act on immediately."
Due to advances in Next Generation Sequencing, Data Driven Medicine is at the forefront of a revolution taking place in the diagnosis and treatment of genetic disease. Increasingly, physicians are demanding more sophisticated analytics to help interpret the results provided by gene sequencing technologies.
Sophia Genetics has developed algorithms based on machine learning and Iterative Bayesian mathematics to build an unbiased view of the data, which is of critical importance to health care providers and research facilities.
About Sophia Genetics
Sophia Genetics has a fundamentally new approach to the development and clinical adoption of Data Driven Medicine, focused on achieving best patient outcomes whilst keeping patients' personal genomic data secure. Its software as a service (SaaS) offering, dropGen,™ covers the bioinformatic analysis protocol, the validation and quality control process, the presentation of results of genetic tests to clinicians and the protection of patient DNA sequence data through safe storage and banking. Sophia Genetics has received ISO 13485 accreditation and is the first European company to obtain a CE-IVD mark for the clinical use of a Next Generation Sequencing (NGS) bioinformatic pipeline for routine genetic testing.
SOURCE Sophia Genetics